Klára Piukovics

TL;DR: In this paper, the authors studied the risk factors for adverse outcomes in patients with hematological malignancies (HM) who developed COVID-19 and analyzed predictors of mortality.

TL;DR: While mortality is significantly lower than in the pre-vaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality.

TL;DR: It is demonstrated that the use of biosimilar rhG-CSF is effective and safe in autologous PBSC mobilization and engraftment after AHSCT and generally well tolerated in theEngraftment setting.

TL;DR: The results showed that the use of routine CMV DNA monitoring is not necessary in patients with haematological malignancies not receiving fludarabine-containing regimen or alemtuzumab, in spite of this to decrease the mortality the authors have to consider theUse of molecular tests in case of suspected infectious conditions.

TL;DR: Three patients had haematological malignancy and severe neutropenia, and three of them suffered from oral mucositis or oedema of the oral mucosal surfaces, which was the probable portal of entry.